Spinogenix key facts
as of Oct 2026- Operator of a biopharmaceutical company intended to restore the brain connections and functions lost in brain injury and neurodegenerative diseases.
- Spinogenix is valued at approximately $335.0M as of Oct 2026, set at its later-stage round, Mar 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $27.4M across 7 recorded rounds; the latest was Early Stage VC ($10.6M) in Nov 2025.
- Notable investors include United States Department of War, University of California, San Diego, Stead Impact Ventures and Foundation, U.S. Department of Health and Human Services.
- Spinogenix has filed 8 Form Ds with the SEC since 2017, most recently Jun 2024 ($2.8M sold to 3 investors).
- Status: Privately Held (backing).
Valued at $335.0M at its later-stage round, Mar 2026. Nothing has traded since.
- ·Watch Spinogenix: the Monday email on marks, rounds and moves
Spinogenix funding rounds
7 roundsSpinogenix valuation
Spinogenix was valued at $335 million at its later-stage round in Mar 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Spinogenix raised?
Spinogenix has raised $27.4 million across 7 recorded rounds since 2017. The largest was a $903,335 seed round in Sep 2017; the most recent was a $10.6 million early-stage round in Nov 2025.
Spinogenix has filed 8 Form Ds with the SEC since 2017, most recently in Jun 2024 ($2.8 million sold to 3 investors).
Spinogenix investors
5 investors are on record for Spinogenix, including United States Department of War, University of California, San Diego and Stead Impact Ventures and Foundation. The early-stage round in Nov 2025 drew 5 investors.
About Spinogenix
Operator of a biopharmaceutical company intended to restore the brain connections and functions lost in brain injury and neurodegenerative diseases. The company offers drugs to reverse synapse loss, restoring connections lost to neurodegenerative diseases and other conditions involving the central nervous system, enabling patients to regenerate synapses through their direct modulation of synaptic proteins.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2016
- Employees
- 5
- Website
- spinogenix.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.